Myomo, Inc., a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury. The company serves orthotics and prosthetics practices or clinics, as well as the veteran administration and other hospitals through orthotics and prosthetics providers, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-996-9058
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable
Myomo (NASDAQ:MYO) Frequently Asked Questions
What is Myomo's stock symbol?
Myomo trades on the NASDAQ under the ticker symbol "MYO."
How were Myomo's earnings last quarter?
Myomo, Inc. (NASDAQ:MYO) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.16). The company earned $0.61 million during the quarter, compared to the consensus estimate of $1.30 million. View Myomo's Earnings History.
When is Myomo's next earnings date?
What is the consensus analysts' recommendation for Myomo?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Myomo.
Has Myomo been receiving favorable news coverage?
Headlines about MYO stock have been trending positive this week, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Myomo earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for Myomo.
Who are some of Myomo's key competitors?
Some companies that are related to Myomo include Azure Healthcare (AZV), Surgical Innovations Group (SUN), Heramed (HMD), Total Brain (TTB), Aurora Spine (ASG), Analytica (ALT), Adherium (ADR), Micron Solutions (MICR), Cannabix Technologies (BLO), COCHLEAR LTD/ADR (CHEOY), Ellex Medical Lasers (ELXMF), GN Store Nord A/S (GGNDF), Micro-X (MX1), Neuroone Medical Technologies (NMTC) and Ortho Regenerative Technologies (ORTH).
Who are Myomo's key executives?
Myomo's management team includes the folowing people:
- Mr. Paul R. Gudonis, Chairman, Pres & CEO (Age 63)
- Ms. Davie Mendelsohn RN, VP of Sales & Clinical Services (Age 64)
- Mr. Jonathan Naft, VP & GM (Age 53)
- Mr. Ralph A. Goldwasser, Chief Financial Officer (Age 70)
- Mr. Clifford J. Conneighton, Chief Marketing Officer (Age 68)
How do I buy shares of Myomo?
Shares of MYO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Myomo's stock price today?
One share of MYO stock can currently be purchased for approximately $0.32.
How big of a company is Myomo?
What is Myomo's official website?
How can I contact Myomo?
The company can be reached via phone at 617-996-9058.
MarketBeat Community Rating for Myomo (NASDAQ MYO)
MarketBeat's community ratings are surveys of what our community members think about Myomo and other stocks. Vote "Outperform" if you believe MYO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYO will underperform the S&P 500 over the long term. You may vote once every thirty days.
